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OBJECTIVE—Excess tissue iron levels are a risk factor for
diabetes, but the mechanisms underlying the association are
incompletely understood. We previously published that mice and
humans with a form of hereditary iron overload, hemochroma-
tosis, exhibit loss of -cell mass. This effect by itself is not
sufﬁcient, however, to fully explain the diabetes risk phenotype
associated with all forms of iron overload.
RESEARCH DESIGN AND METHODS—We therefore exam-
ined glucose and fatty acid metabolism and hepatic glucose
production in vivo and in vitro in a mouse model of hemochro-
matosis in which the gene most often mutated in the human
disease, HFE, has been deleted (Hfe
/).
RESULTS—Although Hfe
/ mice exhibit increased glucose
uptake in skeletal muscle, glucose oxidation is decreased and the
ratio of fatty acid to glucose oxidation is increased. On a high-fat
diet, the Hfe
/ mice exhibit increased fatty acid oxidation and
are hypermetabolic. The decreased glucose oxidation in skeletal
muscle is due to decreased pyruvate dehydrogenase (PDH)
enzyme activity related, in turn, to increased expression of PDH
kinase 4 (pdk4). Increased substrate recycling to liver contrib-
utes to elevated hepatic glucose production in the Hfe
/ mice.
CONCLUSIONS—Increased hepatic glucose production and
metabolic inﬂexibility, both of which are characteristics of type
2 diabetes, may contribute to the risk of diabetes with excessive
tissue iron.
E
merging data demonstrate that iron plays an
important role in metabolic regulation and the
pathophysiology of diabetes. Iron overload is
common in type 2 diabetes (1–3). Conversely,
iron depletion seems to be protective for the development
of diabetes. Rats with iron-deﬁciency anemia are more
insulin sensitive than controls (4), and phlebotomy im-
proves insulin sensitivity and glycemia, both in nondia-
betic subjects (5) and type 2 diabetic subjects with high
ferritin (6). These studies suggest that iron plays an
important role in the development of diabetes. However,
the precise molecular mechanisms of iron-associated dia-
betes are not well understood.
The most commonly studied model for iron-associ-
ated diabetes is hereditary hemochromatosis (HH), a
common autosomal recessive disorder with a preva-
lence of 0.5% in people of northern European ancestry
(7,8). The majority of individuals with HH carry a
mutation (C282Y) in the HFE gene resulting in nonex-
pression of HFE on the cell surface (9,10). Normal HFE
protein is required for iron stimulation of the hepatic
synthesis of hepcidin, a peptide that regulates iron
absorption through the downregulation of iron channel
ferroportin (11). Failure to downregulate ferroportin in
hemochromatosis leads to unlimited iron entry into the
circulation from duodenal cells and macrophages (12).
This results in iron overload in most major organs,
including liver and pancreas (13), although based on the
pathogenesis of the disease, tissues with high ferropor-
tin expression such as enterocytes and macrophages
have decreased iron levels (14). Diabetes is part of the
classic presentation of HH, and our group as well as
others have recently determined that prevalence of
diabetes in persons with HH over the age of 45 exceeds
20% (15,16). We also reported that a mouse model of
hemochromatosis with targeted deletion of the Hfe gene
(Hfe
/), leading to defects in iron handling and iron
overload very similar to the human disease, exhibits
oxidative stress in islets and decreased insulin-secre-
tory capacity (17). These defects, however, are well
compensated in Hfe
/ mice that exhibit supernormal
glucose tolerance and increased glucose uptake in skel-
etal muscle (18). Diabetes in humans with HH usually
occurs in the setting of obesity, wherein it has been
hypothesized that the resultant insulin resistance can-
not be compensated because of the insulin secretory
defect (15).
Other conditions that might predispose to diabetes in
states of iron overload, such as dysregulation of hepatic
glucose production or changes in the capacity to metabo-
lize different fuels, have not been examined. To better
understand the role of iron in diabetes and metabolic
regulation, we have further studied glucose and fatty acid
metabolism in Hfe
/ mice. Hfe
/ mice exhibit a prefer-
ence for fatty acid as well as increased gluconeogenesis.
The increased hepatic glucose production and metabolic
inﬂexibility (19), both of which are characteristic of type 2
diabetes, may contribute to the risk of diabetes with
excessive tissue iron.
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Mice with knockout of the Hfe gene (Hfe
/) (13) were bred onto the
129/SvEvTac and C57BL/6J genetic backgrounds for more than 10 genera-
tions. Normal chow (Harlan Teklad TD-8640) contained 4.5% of calories as fat
and 0.33 g/kg of carbonyl iron. High-fat diet (Research Diets D12451)
contained 45% calories from fat. Mice were fed for a period of 2 months,
beginning at age 4–6 months. Procedures were approved by the Institutional
Animal Care and Use Committee of the University of Utah.
Quantiﬁcation of transcript levels by RT-PCR. Quantative RT-PCR was
performed as described previously (16). Muscle RNA was extracted using the
PureLink Micro-to-Midi Total RNA Puriﬁcation System (Invitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. First-strand cDNA synthesis
was carried out using Superscript III reverse transcriptase (Invitrogen)
according to the manufacturer’s protocol. Real-time PCR was performed with
a thermal cycler (LightCycler, Roche Diagnostics, Basel, Switzerland) as
previously described (20). Primers were designed using Primer3 software
(http://primer3.sourceforge.net). Quantiﬁcation of cDNA products was accom-
plished by the LightCycler software. Messenger RNA levels of speciﬁc genes
were normalized to the average of the cyclophilin and Rpl13a levels for the
same sample.
Measurement of mitochondrial oxygen consumption in skeletal muscle.
Oxygen consumption in isolated muscle mitochondria was measured using a
ﬁber-optic oxygen sensor (Ocean Optics, Orlando, FL) as previously described
(21). Hindlimb soleus muscles were suspended in 2.0 ml of 120 mmol/l KCl, 3
mmol/l HEPES, 5 mmol/l KH2PO4, 1 mmol/l EGTA and 1 mg/ml fatty acid free
BSA, pH 7.2. Respiration assay was performed in a thermostated (25°C),
water-jacketed, sealed glass chamber with constant magnetic stirring. Oxygen
consumption rates were measured for the following substrates: 5 mmol/l
glutamate  2 mmol/l malate in the basal state (state 2), after the addition of
1 mmol/l ADP (to maximally stimulate the respiration, state 3), and in the
presence of 1 g/ml oligomycin to block ATP synthesis (state 4). Respiratory
control ratios were calculated as the ratio of respiration rate in state 3 to that
in state 4.
Glucose oxidation. Soleus muscles were weighed and put in 24-well plates
containing 400-l Krebs-Ringer bicarbonate buffer (2.8 mmol/l glucose, 2
mg/ml BSA, 10 mmol/l HEPES [pH 7.4], 5 mmol/l NaHCO3, 2.2 mmol/l CaCl2,
1.2 mmol/l MgSO4-7H2O, 1.2 mmol/l KH2PO4, 4.8 mmol/l KCl, 126.2 mmol/l
NaCl), pregassed for 30 min with 95% O2/5% CO2. Next, 3 Ci of [U-
14C]
glucose were added to each well for2ha t37°C. Glucose oxidation was
quantiﬁed by measuring
14CO2 release, trapped by paper membranes soaked
with hyamine hydroxide. Background release from a well containing no tissue
was subtracted.
Hearts were perfused in the working mode and glucose oxidation deter-
mined as previously described (22).
Palmitate oxidation. Palmitate oxidation by soleus muscle was assayed as
previously described (23,24) in 500-l Krebs-Ringer bicarbonate buffer con-
taining 1% fatty-acid free BSA, 1 mmol/l carnitine, and 5 Ci of [9,10-
3H]
palmitate. Background
3H2O release measured in a well without tissue was
subtracted from experimental values.
Indirect calorimetry. Mice age 6 to 8 months old were studied for 3
consecutive days in a four-chamber open-circuit Oxymas system (CLAMS;
Columbus Instruments, Columbus, OH) to measure oxygen consumption and
carbon dioxide production.
Hyperinsulinemic euglycemic clamp studies. Studies were performed in
weight-matched nonsedated mice as described (25). The jugular vein was
catheterized under avertin anesthesia, and using Micro-renathane tubing
(Braintree Scientiﬁc, MRE 025). The animals were allowed to recover for 48 h
before undergoing the clamp procedure. Mice were fasted overnight and
transferred to a standard mouse housing cage with a tether arm attached to
the catheter. A dual infusion pump (pump 33, Harvard Apparatus) was used to
infuse insulin at a constant ﬂow rate with no priming dose. A solution of 50%
dextrose was infused at a variable rate to maintain a target value of 100–150
mg/dl and held at that level for 60 min. We also infusted [
3H]glucose at a
constant rate (0.1Ci/min). Glucose was measured using 3 l of tail vein blood
at 10-min intervals using a tail clip and glucometer (Glucometer Elite, Bayer,
Tarrytown, NY). Insulin levels did not differ between the groups, and we also
determined that there was no change in insulin clearance in Hfe
/ mice as
determined from C-peptide/insulin ratios (not shown).
Pyruvate dehydrogenase activity. Pyruvate dehydrogenase (PDH) activity
was examined as described before (26) using a radioactive-enzymatic method.
Frozen skeletal muscle tissue was homogenized in a buffer containing 25
mmol/l HEPES (pH 7.4), 3 mmol/l EDTA, 5 mmol/l sodium dichloroacetate, 1
mmol/l N-{}-tosyl-L-lysylchloromethane, 1 mmol/l ADP, 5 mmol/l dithiothrei-
tol, 2 mmol/l CaCl2, 5 mmol/l MgCl2, and 25 mmol/l KF, supplemented with
1.5% Triton X-100 and 5 mol/l leupeptin. Before the addition of assay buffer,
aliquots of homogenate were incubated at 30°C for 30 min to allow dephos-
phorylation and activation of PDH. Active PDH were determined in a reaction
mixture containing 50 mmol/l HEPES (pH 7.4), 0.4 mmol/l thiamine pyrophos-
phate, 0.4 mmol/l CoA, 2 mmol/l dithiothreitol, 5 mmol/l NAD, and 5 mmol/l
MgCl2, supplemented with 0.17% Triton X-100, 5 units/ml dihydrolipoamide
reductase (E3), 20 l of homogenate, and 2 Ci [1-
14C]-pyruvate. The PDH
reaction yielding acetyl-CoA  CO2 was performed at 30°C for 7 min before
termination of the reaction by the addition of 2 mol/l acetic acid in 2% SDS.
The
14CO2 released from the PDH reaction was trapped by paper membranes
soaked with hyamine hydroxide and quantiﬁed with a scintillation counter
(Beckman Coulter). PDH activity was expressed as nmol  min
1  mg tissue
1.
Measurement of serum lipids and tissue pyruvate, lactate, and glyco-
gen. Age-matched (6–8 month) male mice were killed. Serum triglycerides
and free fatty acids were measured using assay kits from Sigma (St. Louis,
MO) and Roche (Penzburg, Germany), respectively. Tissue was collected and
tissue homogenates were used to assess pyruvate and glycogen levels.
Pyruvate and lactate were measured by assay kits (Biovision, Mountain View,
CA). Liver glycogen was measured as previously described (23).
Pyruvate tolerance testing. Blood glucose was measured with a glucometer
in fasted mice before and after intraperitoneal injection of sodium pyruvate (2
mg/g body weight).
Western blotting for ferritin, AMPK, Akt, IRS2, and ACC. Hind-limb
muscle was collected and tissue homogenates were prepared for Western blot
analysis. Levels of total and/or phosphorylated proteins were detected by
immunoblotting using the following antibodies: Acetyl-CoA carboxylase
(Ser79) (Cell Signaling Technology, Danvers, MA), AMPK (Thr172) (Cell
Signaling Technology), ferritin (Abcam, Cambridge, MA), Akt (Cell Signaling
Technology), and IRS2 (Abcam). Signals quantiﬁed by densitometry were
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels
(Santa Cruz Biotechnology, Santa Cruz, CA) or, in the case of phosphopro-
teins, to the total levels of the same protein.
Statistical procedures. Descriptive statistics are represented as average 
SEM. A two-tailed Student t test was used to compare the differences between
groups.
RESULTS
Skeletal muscle is iron overloaded in Hfe
/ mice. As
previously shown for other tissues (13,27), skeletal muscle
in Hfe
/ mice is iron overloaded, with a 2.3-fold increase
in ferritin compared with muscle of wild-type mice of the
same strain (129SvEvTac, 129) as detected by Western
blotting (P  0.01, Fig. 1A). We have reported that
nonheme iron is also elevated in Hfe
/ muscle (18).
Decreased glucose oxidation but relatively increased
fatty acid oxidation in skeletal and cardiac muscle
from Hfe
/ mice. We previously demonstrated that
Hfe
/ mice exhibited increased muscle glucose uptake
(18). To further study the metabolic fate of absorbed
glucose, glucose oxidation was measured in skeletal and
cardiac muscle. Isolated soleus muscle from 129 Hfe
/
mice exhibited a 33% decrease in glucose oxidation com-
pared with wild type (Fig. 1B, P  0.05). Similar results
were obtained in isolated working hearts (Fig. 1B, P 
0.005). The decreased glucose oxidation, despite elevated
glucose uptake in muscle, are manifest by increased
lactate levels. We previously reported that lactate ﬂuxes
and serum lactate were elevated in Hfe
/ mice (18), and
we have veriﬁed that tissue lactate levels are also in-
creased by 46% in Hfe
/ muscle (9.1  0.9 g lactate/mg
protein in wild-type muscle compared with 13.3  1.1
g/mg in Hfe
/ muscle, N  7, P  0.01, not shown).
We then measured fatty acid oxidation in isolated soleus
muscle. Hfe
/ mice on the 129 or the diabetes- and
obesity-prone C57BL/6J (C57) backgrounds demonstrated
similar level of palmitate oxidation as determined by
measuring
3H2O release from
3H palmitate (Fig. 1C).
However, in the setting of the decreased glucose oxida-
tion, this represents a 47% increase in the ratio of fatty acid
to glucose oxidation in the Hfe
/ compared with wild-
type mice (Fig. 1D, P  0.01). A relative increase in fatty
acid oxidation is supported by decreased serum triglycer-
J. HUANG AND ASSOCIATES
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/ mice (52.3  5.3 mg/dl in wild-type
compared with 31.5  8.6 mg/dl in Hfe
/ mice, N 
6/group, P  0.05) and a trend toward decreased serum
free fatty acids (0.061  0.03 mmol/l in wild-type com-
pared with 0.056  0.025 mmol/l in Hfe
/ mice, P  0.18).
There was no evidence of a change in glycogenolysis
insofar as muscle glycogen levels did not differ between
wild-type and Hfe
/ mice (10.6  1.6 mg/g muscle in type
compared with 8.3  2.2 mg/g in Hfe
/ mice, N 
7/group, P  0.22).
Modestly decreased mitochondrial respiration, in-
creased PDH kinase 4 mRNA and decreased PDH
activity in Hfe
/ muscle. To determine if decreased
mitochondrial function contributed to the decreased glu-
cose oxidation, mitochondrial function was analyzed by
measuring oxygen consumption by permeabilized muscle
ﬁbers. Compared with wild-type mice, mitochondria from
Hfe
/ soleus muscle exhibited only modestly decreased
mitochondrial respiration. Under glutamate/malate-sup-
ported respiration, states 2, 3, and 4 respiration were
apparently reduced by 19% (P  0.05), 8.5% (P  0.22), and
12.4% (P  0.13), respectively (Fig. 2). ATP production
also trended lower in Hfe
/ mice (16%), although not
statistically signiﬁcantly (not shown, P  0.31). Mitochon-
drial density, as assessed by the ratio of mitochondrial to
nuclear DNA, did not differ between wild-type and Hfe
/
mice (0.36  0.06 vs. 0.32  0.06 arbitrary units, respec-
tively, P  0.68).
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FIG. 1. Decreased glucose oxidation and relative preference for fatty acid oxidation in iron-overloaded muscle of wild-type and Hfe
/ mice on
normal chow. A: Quantitation of Western blots for skeletal muscle ferritin in wild-type and Hfe
/ mice on the 129SvEvTac background (5/group).
B, left side: Soleus muscle from 6- to 8-month-old male 129SvEvTac wild type that was exposed to [C
14] glucose and 10 mmol/l insulin. Results
are normalized to muscle weight and presented as cpm/mg (*P < 0.05). B, right side: Glucose oxidation was also determined in hanging working
hearts. C: Fatty acid oxidation in isolated soleus muscles was determined as release of
3H2O from labeled palmitate. (N  7–8 pairs of
muscles/group for each strain, presented as pmol palmitate per mg protein). D: Ratio of fatty acid oxidation to glucose oxidation (from data in
panels A and C, 7 pairs of data per group). *P < 0.01, ‡P < 0.01.
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FIG. 2. Mitochondrial oxygen consumption in skeletal muscle of wild-
type and Hfe
/ mice (129SvEvTac background). Mitochondrial oxygen
consumption was determined in saponin-permabilized soleus muscle
ﬁbers. (N  15–16 ﬁbers/group. Statistical signiﬁcance for differences
by t test: state 2, *P  0.05; state 3, P  0.22; state 4, P  0.13;
respiratory control ratio [RC], P  0.46).
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/ mice, candidate gene expression was assessed in
muscle using quantitative RT-PCR (Fig. 3A). Carnitine
palmitoyl transferase b (Cpt1b) mRNA was increased by
74% and Pdk4 mRNA by 94% in Hfe
/ mice compared
with wild-type mice (P  0.05). Fatty acid synthase mRNA
was decreased by 41% in the Hfe
/ mice, although this
difference did not reach statistical signiﬁcance (P  0.08).
Transcripts of several other genes involved in nutrient
transport or metabolism (Acl, Cd36, Acox1, Mcad, Lcad,
Pdk1, Ldh , Glut4, and Hif1) did not differ. Because
Pdk4 and Cpt1b are PPAR	 targets, we also measured
PPAR	 mRNA levels, but PPAR	 did not differ between
wild-type and Hfe
/ mice (7% decrease in Hfe
/ mice,
P  0.48, not shown).
The change in pdk4 mRNA possibly explains decreased
glucose oxidation because PDH kinase 4 (PDK4) phos-
phorylates and inhibits PDH, inhibiting pyruvate entry into
the trichloroacetic acid; tricarboxylic acid (TCA) cycle
(28). We therefore assessed the active fraction of PDH in
soleus muscle, which was decreased by 34% in Hfe
/
compared with wild-type soleus muscle (Fig. 3B, P 
0.001). Total PDH activity did not differ between the two
strains (18% increase in Hfe
/ mice, P  0.45, not shown).
Increased fatty acid oxidation, increased oxygen con-
sumption, and decreased respiratory exchange ratio
in Hfe
/ mice on a high-fat diet. Fatty acids are
relatively preferred as a fuel in muscle of Hfe
/ mice on
a normal (high carbohydrate) chow diet. We therefore
examined fatty acid oxidation in muscle of Hfe
/ mice on
a high-fat diet, and in this case, isolated soleus muscle
from Hfe
/ mice demonstrated an absolute increase in
the capacity for fatty acid oxidation compared with wild
type (Fig. 4A, P  0.05). Consistent with their roles in
regulating fatty acid oxidation, levels of pAMPK and pACC
were increased in skeletal muscle of Hfe
/ mice on high
fat (Fig. 4B and C).
The preference for fatty acid oxidation in Hfe
/ mice on
a high-fat diet was conﬁrmed in studies of mice in metabolic
chambers. Hfe
/ mice on a high-fat diet exhibited signiﬁ-
cant increases in oxygen consumption (Fig. 4D) and heat
production (Fig. 4E) compared with wild type. These were
not speciﬁc to mouse strain, as the differences were signiﬁ-
cant for mice on either the 129 or C57Bl6 backgrounds.
Hfe
/ mice on the high-fat diet also had signiﬁcantly lower
respiratory exchange ratios (Fig. 4F). Differences between
Hfe
/ and wild type in heat production and respiratory
exchange ratios were not apparent in mice fed the predom-
inantly carbohydrate normal chow (not shown). In fact,
Hfe
/ mice on both the 129 and C57 genetic backgrounds
have lower oxygen consumption rates on high carbohydrate
chow (25%, P  0.05, not shown), consistent with their
decreased glucose oxidation rates on the same diet (Fig. 1B).
Increased hepatic glucose output in Hfe
/ mice. To
better understand the overall fuel economy in the Hfe
/
mice, we next measured hepatic glucose output (HGO) by
means of the hyperinsulinemic euglycemic clamp. HGO
was suppressed at maximal 10 mU/kg/min insulin in both
wild-type and Hfe
/ mice (not shown), but at submaxi-
mal 5 mU/kg/min insulin, HGO was increased by 4.5-fold in
Hfe
/ mice on normal chow and 1.7-fold on high fat (Fig.
5A, P  0.001). The increased HGO did not appear to stem
from an overall stimulation of the pathway for gluconeo-
genesis, as the mRNAs for phosphoenolpyruvate car-
boxykinase (PEPCK) and glucose-6-phosphatase (G6Pase)
were not increased in livers of Hfe
/ mice (Fig. 5B).
Consistent with this lack of upregulation of gluconeogenic
enzymes, pyruvate tolerance testing revealed no difference
in glucose production between wild-type and Hfe
/ mice
(Fig. 5C). The increased HGO also did not stem from
insulin resistance or insulin deﬁciency: We previously
reported that glucose disposal determined by glucose
clamp is elevated in Hfe
/ mice on normal chow at
submaximal but not maximal glucose (18), and glucose
disposal also trended toward an increase in the Hfe
/
mice on high fat compared with wild type (157  36 vs.
95  10 mg/kg/min, P  0.13, not shown). Furthermore,
hepatic insulin signaling was augmented in the Hfe
/
mice on normal chow. Fasted mice exhibited a 1.6-fold
increase in phosphorylated Akt (pAkt) and a 2.3-fold
increase in tyrosine phosphorylation of insulin receptor
substrate-2 (pIRS2) (Fig. 5D and E, P  0.05 for both). The
source of the higher HGO also did not appear to be
increased glycogenolysis, as hepatic glycogen levels were
increased by 65.7% in Hfe
/ mice compared with wild-
type mice (Fig. 5F, P  0.05). Pyruvate levels were
increased by 32% in livers of Hfe
/ mice (Fig. 5F, P 
0.01). Unlike the case in skeletal muscle, however, in liver
there was no evidence for a decrease in pyruvate entry
into mitochondrial oxidative pathways. Levels of Pdk1 and
Pdk2 were in fact signiﬁcantly lower in the Hfe
/ liver,
which would favor increased PDH activity and decreased
pyruvate levels; Pdk’s 3 and 4 were undetectable. The
mRNA for pyruvate carboxylase (PCX) which catalyzes
pyruvate conversion to oxaloacetate for either gluconeo-
genesis or anaplerotic entry of pyruvate into the TCA cycle
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FIG. 3. Mechanism for decreased glucose oxidation in skeletal muscle of
wild-type and Hfe
/ mice: Increased Pdk4 and cpt1b mRNA, and de-
creased pyruvate dehydrogenase (PDH) activity. A: Expression of candi-
date genes in muscle of Hfe
/ mice and wild-type mice (129SvEvTac
background) on normal chow, quantitated by RT-PCR (cDNA from seven
mice per group, *P < 0.05). B: Soleus muscle PDH activity assayed in vitro
in wild-type and Hfe
/ mice (N  5/group, ‡P < 0.005).
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/ mice
compared with wild-type mice (Fig. 5G, P  0.05). Both of
these changes in liver would actually favor increased
mitochondrial utilization of pyruvate in Hfe
/ liver. In
sum, therefore, the data above suggest that the increased
pyruvate and HGO largely result from increased peripheral
cycling rather than decreased hepatic utilization.
DISCUSSION
Increased tissue iron levels are associated with diabetes,
both in human hereditary hemochromatosis (HH) and in
dietary iron overload (1,3,15,29,30). Although this is at
least partially the result of decreased insulin secretion
(15,17,27), tissue iron overload also results in signiﬁcant
changes in glucose metabolism in skeletal muscle (18). In
that case, however, the effect of iron is to increase glucose
uptake, a change that would be predicted to be protective
of diabetes. To better understand the changes in overall
fuel economy caused by iron that might contribute to
diabetes, we have investigated muscle and hepatic carbo-
hydrate and fatty acid metabolism in a mouse model with
targeted deletion of the gene most commonly mutated in
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FIG. 4. Hfe
/ mice on a high-fat diet exhibit increased fatty acid oxidation and activation of AMPK in muscle, and hypermetabolism with
a lower respiratory exchange ratio in vivo. Eight-month-old wild-type and Hfe
/ mice were fed a high-fat diet for 8 weeks before the study.
A: Fatty acid oxidation in isolated soleus muscles of mice on the 129SvEvTac background was determined as release of
3H2O from labeled
palmitate. (N  5–6 pairs of muscles/group, presented as pmol palmitate per mg protein.) B: Muscle tissue from wild-type and Hfe
/ mice
on the 129SvEvTac background was analyzed by Western blotting for activated pAMPK, total AMPK, and pACC, with GAPDH protein as a
loading control shown for each gel. C: Densitometric data from four independent determinations per group were quantitated and normalized
to GAPDH. D–F: Wild-type and Hfe
/ mice on either the 129SvEvTac or C57BL6/J genetic backgrounds were studied for 3 consecutive days
by indirect calorimetry. D: Oxygen consumption. E: Heat production. F: Respiratory exchange ratio, the ratio of CO2 production to O2
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/ mice exhibit a shift
in fuel preference from glucose to fatty acid oxidation in
muscle. The decreased glucose oxidation in muscle is
associated with increased pyruvate/lactate recycling to
liver, as demonstrated in our previous metabolic ﬂux
studies (18), in Fig. 5, and by the increased hepatic glucose
output. These combined effects may contribute to the
increased prevalence of diabetes in individuals with HH.
Our results are consistent with the close coupling of
metabolism to iron availability such as has been demon-
strated in lower eukaryotes (31–33). The decreased glu-
cose oxidation in skeletal muscle is due, at least in part, to
decreased PDH activity. The mechanism is likely the
observed increase in Pdk4 mRNA, PDK4 activity being
largely regulated at the transcriptional level (28). A candi-
date mediator for the regulation of Pdk4 may be increased
AMPK activity (34) that we previously reported in Hfe
/
mouse muscle (18). Other factors contributing to the
decreased glucose oxidation include a modest degree of
mitochondrial dysfunction and increased fatty acid oxida-
tion (Randle effect) (35). The mitochondrial dysfunction in
Hfe
/ muscle is likely, however, to be a relatively minor
contributor given the increased capacity for fatty acid
oxidation apparent in mice on high-fat diets.
The mechanism for the increased fatty acid oxidation is
also likely multifactorial. We previously reported higher
serum adiponectin levels in Hfe
/ mice (18) that would
contribute to higher rates of fatty acid oxidation through
increased AMPK activation and decreased ACC activity
(36,37). Increased Cpt1b expression may also play a role,
as might changes in malonyl-CoA, which were not as-
sessed. Perhaps related to the current ﬁndings, mice
overexpressing erythropoietin in muscle exhibit a similar
phenotype to iron-overloaded mice, including increased
fat oxidation, decreased glucose oxidation, and protection
from diet-induced obesity, although tissue iron levels were
not measured in that model (38). Insofar as iron sufﬁciency
should facilitate unimpaired erythropoiesis, it would seem
advantageous for an iron-sufﬁcient mouse to shift to the
more energy-efﬁcient but oxygen-inefﬁcient fuel source of
fatty acids to make use of that full capacity for oxygen
transport. Indeed, under the opposite condition of hyp-
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metabolism downregulate, and glucose oxidation in-
creases (39,40). Consistent with this proposed adaptive
relationship between iron and fuel choice, Hfe
/ mice
consume more oxygen and produce more heat when fat is
available in the diet. A decreased ability to transition
between utilization of carbohydrate and lipid fuel sources,
so-called “metabolic inﬂexibility,” is a characteristic of the
metabolic syndrome and type 2 diabetes (19). Chronically
increased fat oxidation, especially in the setting of de-
creased mitochondrial function, might also contribute to
the accumulation of lipid products that have been impli-
cated in the pathogenesis of diabetes (41). Whether these
pathways contribute to increased diabetes risk in human
hemochromatosis, however, is unknown.
The data are most consistent with the source of the
increased hepatic glucose production being increased
recycling of lactate and pyruvate, as was also previously
documented by isotopomer analysis of the fate of
1,2[
13C]glucose (18). It appears that this increase in he-
patic glucose production is mainly substrate driven as the
levels of mRNA for gluconeogenic enzymes were not
increased (Fig. 5B) and glucose production from exoge-
nous pyruvate was not enhanced (Fig. 5C). The data also
do not support changes in insulin signaling as the under-
lying cause of the phenotype. We previously demonstrated
no change in basal or insulin-stimulated (in vivo) pAkt in
skeletal muscle (18), and herein we shown that the in-
creased hepatic glucose production occurs in the face of
paradoxically increased insulin signaling in liver (Fig. 5D
and E). Why insulin signaling is upregulated is not known.
Levels of the insulin-sensitizing adipokine have been
shown to be elevated in Hfe
/ mice (18), but other
unknown factors may also contribute, including compen-
sation for decreased insulin levels (17) or decreased
inﬂammatory signaling in macrophages based on their
lower iron content (42). Why this increased insulin signal-
ing does not translate to decreased levels of gluconeogenic
enzymes is unclear and is under investigation.
In sum, we have shown here and in previous work that
the diabetes risk engendered by iron operates not only
through its toxic effects on  cells mediated by increased
oxidative stress and mitochondrial dysfunction. Rather,
iron also exerts regulatory effects on metabolism and fuel
choice. Iron overloaded skeletal muscle demonstrates
decreased glucose oxidation and increased fatty acid
oxidation. Liver of Hfe
/ mice exhibits increased glucose
output, with the patterns of hepatic gene regulation and
metabolite levels suggesting that the gluconeogenesis is
largely substrate-driven and results from the altered fuel
choice in muscle. These ﬁndings should help elucidate the
association between iron and diabetes, not only in hemo-
chromatosis, but also in nonhemochromatotic individuals
with the metabolic syndrome or type 2 diabetes associated
with dietary iron excess.
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